TMCnet News
Life Sciences Summit Will Showcase Immunomic TherapeuticsOn Wednesday, Nov. 2, Immunomic Therapeutics CEO, Dr. William Hearl will speak on Immuno-oncology and the future of personalized medicine. The panel will discuss immuno-oncology therapies applied to the most difficult to treat cancers including metastatic kidney cancer, metastatic melanoma, and lung cancer, among others. The panel will explore top-of-mind questions on immunotherapies including why all patients do not respond equally, or at all, and methods of predicting effective therapies for diverse cases. Who: Dr. William Hearl, CEO, Immunomic Therapeutics What: Panel discussion titled Immuno-Oncology: Cracking the Code of Personalized Medicine; open to conference attendees and media When: Wednesday, Nov. 2, 1:15 pm EST
Where: 10 on the Park at Time Warner (News - Alert) Center, 60 Columbus Circle 10 About ITI Immunomic Therapeutics, Inc. is a privately-held, clinical stage biotech company on a mission to pioneer vaccines that transform lives. The company, based in Rockville, MD, is developing nucleic acid vaccines based on the patented Lysosomal Associated Membrane Protein (LAMP) Technology. Termed LAMP-Vax™, the exclusive immunotherapy technology works with the body's natural biochemistry system and has the potential to improve a broad range of vaccines. ITI entered into a licensing agreement with Astellas Pharma Inc. in 2015 to explore the use of LAMP-Vax in the prevention and treatment of allergic diseases, and is now focused on cancer immunotherapy. The LAMP platform has been tested in Phase I and II clinical studies. For more information, please visit www.immunomix.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161031005622/en/ |